| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Biogen Inc. | Bardoxolone - (FALCON) | Chronic Kidney Disease | Phase 3 | Trial Discontinued | Oral | N/A |
| Biogen Inc. | Bardoxolone methyl - CATALYST | Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Biohaven Ltd. | BHV-8000 | Multiple Sclerosis | Phase 2 | Ongoing | Oral | Neurology |
| Biohaven Ltd. | Nurtec ODT (rimegepant) | Chronic rhinosinusitis (CRS) with or without nasal polyps | Phase 2/3 | Trial Completed | Oral | Respiratory |
| Biohaven Ltd. | Taldefgrobep alfa | Obesity | Phase 2 | Ongoing | Intramuscular | Endocrinology |
| Biohaven Ltd. | BHV-2100 | Acute migraine | Phase 2 | Ongoing | Intravenous | Neurology |
| Biohaven Ltd. | Troriluzole | Obsessive compulsive disorder (OCD) | Phase 3 | Ongoing | Oral | Psychiatric |
| Biohaven Ltd. | Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) | Glioblastoma (GBM) | Phase 2/3 | Trial Completed | Oral | Oncology |